n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with Glaucoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donegan, RK; Lieberman, RL | 1 |
| Bar-Yehuda, S; Cohen, S; Fishman, P | 1 |
2 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Glaucoma
| Article | Year |
|---|---|
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
Topics: Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Drug Discovery; Glaucoma; Humans; Ligands; Protein Kinase Inhibitors; rho-Associated Kinases; Sympathomimetics | 2016 |
Targeting the A3 adenosine receptor for glaucoma treatment (review).
Topics: Adenosine; Adenosine A3 Receptor Agonists; Anti-Inflammatory Agents; Apoptosis; Dry Eye Syndromes; Glaucoma; Humans; Intraocular Pressure; Receptor, Adenosine A3; Retinal Ganglion Cells | 2013 |